Aleksandr Ianevski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6118740/publications.pdf

Version: 2024-02-01

318942 299063 2,802 46 23 42 citations h-index g-index papers 59 59 59 5331 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Research, 2020, 48, W488-W493.	6.5	545
2	SynergyFinder: a web application for analyzing drug combination dose–response matrix data. Bioinformatics, 2017, 33, 2413-2415.	1.8	403
3	Discovery and development of safe-in-man broad-spectrum antiviral agents. International Journal of Infectious Diseases, 2020, 93, 268-276.	1.5	169
4	Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data. Nature Communications, 2022, 13, 1246.	5.8	163
5	SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Research, 2022, 50, W739-W743.	6.5	139
6	Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood, 2020, 135, 597-609.	0.6	134
7	Prediction of drug combination effects with a minimal set of experiments. Nature Machine Intelligence, 2019, 1, 568-577.	8.3	99
8	Potential Antiviral Options against SARS-CoV-2 Infection. Viruses, 2020, 12, 642.	1.5	92
9	Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection inÂvitro and differentially affect cellular signaling, transcription and metabolism. Antiviral Research, 2017, 139, 117-128.	1.9	88
10	Low Temperature and Low UV Indexes Correlated with Peaks of Influenza Virus Activity in Northern Europe during 2010–2018. Viruses, 2019, 11, 207.	1.5	81
11	Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine. Viruses, 2019, 11, 964.	1.5	68
12	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics, 2020, 36, 3602-3604.	1.8	68
13	Common Nodes of Virus–Host Interaction Revealed Through an Integrated Network Analysis. Frontiers in Immunology, 2019, 10, 2186.	2.2	67
14	Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research, 2018, 154, 174-182.	1.9	64
15	Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19. Viruses, 2021, 13, 651.	1.5	50
16	Identification and Tracking of Antiviral Drug Combinations. Viruses, 2020, 12, 1178.	1.5	48
17	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. MBio, 2021, 12, e0334721.	1.8	45
18	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. PLoS Computational Biology, 2020, 16, e1007604.	1.5	43

#	Article	IF	CITATIONS
19	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. Viruses, 2017, 9, 271.	1.5	39
20	RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia, 2021, 35, 1087-1099.	3.3	32
21	Expanding the activity spectrum of antiviral agents. Drug Discovery Today, 2019, 24, 1224-1228.	3.2	31
22	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science Advances, 2021, 7, .	4.7	28
23	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. Journal of Medicinal Chemistry, 2021, 64, 8486-8509.	2.9	28
24	Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	27
25	Interactive visual analysis of drug–target interaction networks using Drug Target Profiler, with applications to precision medicine and drug repurposing. Briefings in Bioinformatics, 2018, , .	3.2	25
26	Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS. Blood Cancer Discovery, 2021, 2, 238-249.	2.6	25
27	Integrated root phenotypes for improved rice performance under low nitrogen availability. Plant, Cell and Environment, 2022, 45, 805-822.	2.8	23
28	Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections. Viruses, 2021, 13, 2489.	1.5	20
29	Mono- and combinational drug therapies for global viral pandemic preparedness. IScience, 2022, 25, 104112.	1.9	19
30	Genome-wide off-targets of drugs: risks and opportunities. Cell Biology and Toxicology, 2019, 35, 485-487.	2.4	16
31	Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2. Viruses, 2021, 13, 1768.	1.5	15
32	DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs). Nucleic Acids Research, 2022, 50, W272-W275.	6.5	15
33	Neural signaling modulates metabolism of gastric cancer. IScience, 2021, 24, 102091.	1.9	14
34	Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. Cancers, 2020, 12, 1694.	1.7	13
35	A Systems Approach to Study Immuno- and Neuro-Modulatory Properties of Antiviral Agents. Viruses, 2018, 10, 423.	1.5	10
36	Computational Drug Repositioning and Experimental Validation of Ivermectin in Treatment of Gastric Cancer. Frontiers in Pharmacology, 2021, 12, 625991.	1.6	7

#	Article	IF	CITATIONS
37	High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. Scientific Reports, 2021, 11, 14755.	1.6	7
38	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. HemaSphere, 2022, 6, e701.	1.2	4
39	Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells. Methods in Molecular Biology, 2022, 2449, 327-348.	0.4	4
40	Active Components of Commonly Prescribed Medicines Affect Influenza A Virus–Host Cell Interaction: A Pilot Study. Viruses, 2021, 13, 1537.	1.5	3
41	Safe-in-Man Broad Spectrum Antiviral Agents. Advances in Experimental Medicine and Biology, 2021, 1322, 313-337.	0.8	1
42	Single Passage of Human Metapneumovirus in LLC-MK2 Cells Does Not Affect Viral Protein-Coding Capacity. Genome Announcements, 2018, 6, .	0.8	0
43	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		О
44	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		0
45	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		О
46	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		O